Citations

Clear

16280 citation(s) found for "Yu, David".

Lymphocyte Kinetics and Outcomes of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma With Out of Specification Products
Dingli, Sarah , Rothweiler, Paul , Binder, Moritz , Cook, Joselle , Gertz, Morie A. , Hayman, Suzanne R. , Kapoor, Prashant , Kourelis, Taxiarchis , Kumar, Shaji , Warsame, Rahma , Lin, Yi , Erdman, Arthur G. , Dingli, David , Kumar, Shaji K , Warsame, Rahma , Dingli, David , Gertz, Morie A , Binder, Moritz , Cook, Joselle M , Siddiqui, Mustaqeem

Mayo Clinic

American Journal of Hematology | July 15, 2025 | Volume: 100 | Issue: 9 | Pages: 1705-1708

10.1002/ajh.70001 | PMID 40662471 Get It

In-Bore MRI-Guided Ureteral Stent Placement During Prostate Cancer Cryoablation—A Case Series
Whalen, Sydney, Woodrum, David A. , Adamo, Daniel A. , Lomas, Derek J. , Mynderse, Lance A. , Woodrum, David, Adamo, Dan , Lomas, Derek , Mynderse, Lance , Whalen, Sydney, Thompson, Scott M.

Mayo Clinic

Diagnostics | July 15, 2025 | Volume: 15 | Issue: 14 | Pages: 1781

10.3390/diagnostics15141781 | PMID 40722529 Get It

Introduction: Ureteral stents are widely used in the specialty of urology to preserve renal function and provide ureteral patency in cases of urolithiasis, strictures, malignancy, and trauma. This paper presents a novel application of prophylactic ureteral stents deployed under MRI-guidance for ureteral protection in the setting of in-bore salvage cryoablation therapy for recurrent and metastatic prostate cancer. This is the first known case series of ureteral stent placement using near real-time MRI. Materials and Methods: A retrospective chart review was performed for all patients who underwent MRI-guided ureteral stent placement prior to in-bore cryoablation therapy from 2021 to 2022. Each case was managed by an interdisciplinary team of urologists and interventional radiologists. Preoperative and postoperative data were collected for descriptive analysis. Physics safety testing was conducted on the cystoscope and viewing apparatus prior to its implementation for stent deployment. Results: A total of seven males, mean age 73.4 years (range 65–81), underwent successful prophylactic, cystoscopic MRI-guided ureteral stent placement prior to cryoablation therapy of their prostate cancer. No intraoperative complications occurred. A Grade 2 postoperative complication of pyelonephritis and gross hematuria following stent removal occurred in one case. The majority of patients were discharged the same day as their procedure. Conclusions: This case series demonstrates the feasibility of in-bore cystoscopic aided MRI guidance for ureteral stent placement. Ureteral stents can be used to increase the safety margin of complex cryoablation treatments close to the ureter. Furthermore, by following the meticulous MRI safety protocols established by MRI facility safety design guidelines, MRI conditional tools can aid therapy in the burgeoning interventional MRI space.
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
Chen, Charles D., Jack, Clifford R. , Koeppe, Robert, Hornbeck, Russ C. , Koudelis, Deborah, Keefe, Sarah , Aggarwal, Neelum T. , Bird, Thomas D. , Black, Sandra E., Chhatwal, Jasmeer P. , Day, Gregory S. , Farlow, Martin R. , Gauthier, Serge , Honig, Lawrence S., Xiong, Chengjie , Masellis, Mario, Méndez, Patricio Chrem, Ringman, John M. , Snider, B. Joy, Salloway, Stephen, Dyck, Christopher H. van , Klein, Gregory , Clifford, David B. , Hassenstab, Jason , Mills, Susan L., Perrin, Richard J., Supnet, Charlene , Wang, Guoqiao , Xiong, Chengjie , Team, for the DIAN‐TU Study, Jack, Clifford R , Day, Gregory S , Xiong, Chengjie , Chen, Charles D , Hassenstab, Jason , Supnet-Bell, Charlene , McCullough, Austin , Gordon, Brian A. , Joseph‐Mathurin, Nelly , McKay, Nicole S. , Hobbs, Diana A. , Flores, Shaney , Allegri, Ricardo , Berman, Sarah , Black, Sandra E. , Brooks, William S. , Fox, Nick C. , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jucker, Mathias , Masters, Colin L. , Schofield, Peter R. , Shimada, Hiroyuki , Suzuki, Kazushi , Cruchaga, Carlos , Li, Yan , McDade, Eric , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Team, for the DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | July 15, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70347 | PMID 40660741 Get It

Abstract INTRODUCTION Monoclonal anti‐amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD). METHODS In the DIAN‐TU‐001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [ 11 C]‐Pittsburgh compound‐B (PiB) positron emission tomography (PET), [ 18 F]‐fluoro‐2‐deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI). RESULTS Gantenerumab significantly reduced PiB‐PET uptake overall and in most regions and showed no changes in FDG‐PET or MRI measures. Drug effects were associated with baseline PiB‐PET uptake, and the largest effects occurred in medial regions. DISCUSSION Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB‐PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design. Highlights Gantenerumab unevenly decreased Aβ burden as measured by PiB‐PET across brain regions. The strongest decrease in PiB‐PET uptake was in basal ganglia and medial frontal structures. Variable drug effect on Aβ was partly due to the amount of burden present before treatment. There was no regional effect on FDG‐PET metabolism or MRI volumetrics after 4 years.
CORR Insights®: Is There Any Association Between Orientation of the Lumbar Facet Joints and Increasing Age in White and Black Patients?
Ring, David , Crijns, Tom Joris

Mayo Clinic

Clinical Orthopaedics & Related Research | July 14, 2025 | Volume: 483 | Issue: 8 | Pages: 1563-1565

10.1097/corr.0000000000003597 | PMID 40658516 Get It

Sequence variability of BamA and FadL candidate vaccinogens suggests divergent evolutionary paths of Treponema pallidum outer membrane proteins
Bettin, Everton B. , Aghakhanian, Farhang , Hennelly, Christopher M. , Chen, Wentao , Davenport, Timothy C. , Hackl, Simon T. , Grassmann, André Alex , Vargas-Cely, Fabio Samir , Silva, Sebastián , Luna, Jonny Alejandro García , Jiang, Yinbo , Yang, Ligang , Zheng, Heping , Pospíšilová, Petra , Šmajs, David , Matoga, Mitch , Hoffman, Irving , Moody, M. Anthony , Salazar, Juan C. , Radolf, Justin D. , Vargas-Cely, Fabio, Šmajs, David , Caimano, Melissa J , Hawley, Kelly L , Radolf, Justin D , Ramirez, Lady Giovanna , Yang, Bin , López‐Medina, Eduardo , Nieselt, Kay , Seña, Arlene C. , Parr, Jonathan B.

Mayo Clinic

Journal of Bacteriology | July 14, 2025 | Volume: 207 | Issue: 8 | Pages: No page available

10.1128/jb.00159-25 | PMID 40802283 Get It

ABSTRACT Knowledge of Treponema pallidum subspecies pallidum ( TPA ) outer membrane protein (OMP) sequence variability is essential for understanding spirochete proliferation within endemic populations as well as the design of a globally effective syphilis vaccine. Our group has identified extracellular loops (ECLs) of TPA BamA (TP0326) and members of the FadL family (TP0548, TP0856, TP0858, TP0859, and TP0865) as potential components of a multivalent vaccine cocktail. As part of a consortium to explore TPA strain diversity, we mapped the variability of BamA and FadL orthologs in 186 TPA strains from Malawi, China, and Colombia onto predicted 3D structures. The 186 genomes fell into eight subclades (five Nichols- and three SS14-lineage) with substantial geographic restriction. Single nucleotide variants accounted for the large majority of proteoforms, with variability notably higher within the Nichols-lineage strains. Most mutations were in regions of the proteins predicted to be extracellular and harboring B cell epitopes. We observed a striking difference in the degree of variability between the six OMPs, suggesting that these proteins are following divergent evolutionary paths. Concatenation of OMP sequences recapitulated the phylogenetic structure of the TPA strains, effectively segregating within clades and largely clustering by subclades. Finally, we noted that BamA and FadL candidate ECL vaccinogens, previously shown to elicit antibodies that kill treponemes during in vitro cultivation, are well conserved. Taken as a whole, our study establishes a structural-phylogenetic approach for analyzing the forces shaping the host-pathogen interface in syphilis within endemic populations while informing the selection of vaccine targets. IMPORTANCE Syphilis remains a major global health concern, reinforcing the need for a safe and effective vaccine. Understanding the variability of TPA OMPs is essential for tracking pathogen evolution and informing vaccine design. Here, we analyzed the variability of six TPA OMPs in 186 strains from Malawi, China, and Colombia, identifying protein-specific evolutionary patterns. Most mutations were localized in extracellular regions and, notably, appeared to correlate with the phylogenetic structure of TPA . Despite OMP heterogeneity, several candidate vaccinogens remained highly conserved, reinforcing their potential as globally effective vaccine targets. Our study establishes a structural-phylogenetic framework for dissecting the forces shaping the host-spirochete interface within endemic populations and provides a foundation for designing a globally effective syphilis vaccine.
Cutaneous Nodules and Inflammatory Arthritis: Two Illustrative Cases of Rare Mimics of Rheumatoid Arthritis
Yaman, Reena , DiCaudo, David J. , Pham, Michael M., Griffing, W. Leroy , Sullivan, Megan M. , Aslam, Fawad , Sullivan, Megan M , Yaman, Reena N , Sokumbi, Olayemi , Pham, Michael M., Aslam, Fawad

Mayo Clinic

Journal of Clinical Medicine | July 14, 2025 | Volume: 14 | Issue: 14 | Pages: 4940

10.3390/jcm14144940 | PMID 40725633 Get It

Background: Rheumatoid arthritis is a relatively common rheumatic disease that can present with inflammatory arthritis and subcutaneous nodules. Multicentric reticulohistiocytosis and fibroblastic rheumatism are rarer entities that also present with these features. Methods: Two cases, one of each of fibroblastic rheumatism and multicentric reticulohistiocytosis, are described highlighting characteristic clinical, radiographic, and histologic findings. A narrative review of the literature on these rarer conditions, compared with rheumatoid arthritis, is provided with a focus on articular and cutaneous findings, available information on disease presentations, and key contrasting features that can aid in diagnosis. Results: Radiographic erosion distribution and joint space narrowing, clinical nodule distribution and characteristics, and nodule histology can differ between these diseases. Conclusions: Multicentric reticulohistiocytosis and fibroblastic rheumatism should be considered in the evaluation of seronegative rheumatoid arthritis, especially in cases that do not respond predictably to standard therapies, and cutaneous nodule biopsy can aid in differentiating these three conditions.
To trial or not to trial before peripheral nerve stimulation for chronic pain: a retrospective multicenter comparative analysis of temporary-to-permanent and direct-to-permanent implantation approaches
D’Souza, Ryan S. , Yu, Yue , Singh, Vinita , Javed, Saba , Her, Yeng F , Chai, Nita, Hussain, Nasir , Karri, Jay , Javed, Saba , Hoffmann, Chelsey , Hussain, Nasir , D'Souza, Ryan S , Singh, Vinita , Karri, Jay , Warner, David O.

Mayo Clinic

Regional Anesthesia & Pain Medicine | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-106734

10.1136/rapm-2025-106734 | PMID 40659443 Get It

Background Peripheral nerve stimulation (PNS) is an emerging neuromodulation therapy for chronic pain, yet its use in clinical practice varies significantly. Although temporary PNS is widely incorporated, either as a screening trial or a treatment itself, the evidence supporting the use of temporary PNS prior to permanent implantation is limited. We aimed to compare pain relief, opioid consumption, and adverse events between an approach implementing temporary PNS before permanent implantation (temporary-to-permanent (TTP)) vs proceeding directly to permanent PNS implantation (direct-to-permanent (DTP)). Methods A multicenter retrospective study was undertaken at seven major academic institutions from January 1, 2014, to January 1, 2024. Adult patients who underwent permanent PNS implantation for the treatment of chronic pain conditions were included and were divided into TTP or DTP cohorts based on their clinical approach. The dual primary outcomes were pain relief and opioid consumption (in oral morphine equivalents) at 6 months compared with baseline before any PNS therapy. Multivariable Tobit regression analysis was performed to identify predictors of pain relief at 6 months using a stepwise approach. Results A total of 130 patients were analyzed (54 in TTP approach, 76 in DTP approach). Patient-reported percentage pain relief was 56.7%±27.9% at 6 months compared with baseline (before PNS implantation) in the TTP cohort, and 45.1%±33.6% in the DTP cohort. The estimated mean percentage pain relief at 6 months was similar in the TTP and DTP cohorts (between-group difference 15.24%; 95% CI −0.32 to 30.80, p=0.052), with consistent findings after sensitivity analysis with multiple imputation. Opioid consumption declined similarly in the TTP (−3.1±9.9 mg) and DTP (−2.1±8.1 mg) cohorts at 6 months with no statistical difference between cohorts (mean between-group difference: −1.00, 95% CI −4.57 to 2.57, p=0.580), and with consistent findings after sensitivity analysis. Device explantation rates and adverse event profiles were comparable between cohorts. Conclusion Although temporary PNS is widely performed prior to permanent PNS implantation, there was no evidence that the TTP approach is associated with superior analgesic outcomes compared with the DTP approach. Further, patients in both approaches achieved clinically meaningful pain relief at 6 months compared with baseline status prior to PNS therapy.
E-291 Magnetic capture of autologous mesenchymal stem cells promotes the rapid endothelialization of peripheral venous stents in rabbits
Oliver, A, Cortese, Jonathan, Ding, Yumei , Christensen, T. , Gamb, Scott I., Ranatunga, Wasantha , Carlson, K.D., Teffth, B, Kadirvel, R, Dragomir‐Daescu, Dan , Kallmes, D, Cortese, Jonathan , Dai, Daying , Bayraktar, E, Christensen, T, Hajj, G El , Ognard, Julien , Carlson, K, Pandey, M, Guillory, Roger J. , Kallmes, David F.

Mayo Clinic

SNIS 22nd annual meeting electronic poster abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A291.2-A292

10.1136/jnis-2025-snis.406 Get It

E-268 Lack of specific animal model for venous sinus stenting : a systematic review and standardized evaluation
Bayraktar, Evren , Kadirvel, R, Kallmes, D, Brinjikji, Waleed , Ognard, Julien , Hajj, G El , Ghozy, Sherief , Kadirvel, Ramanathan , Kallmes, David F.

Mayo Clinic

SNIS 22nd annual meeting electronic poster abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A277.1-A277

10.1136/jnis-2025-snis.383 Get It

E-221 Simply the (B)EST : what the neurointerventionalist needs to know about (bleomycin) electrosclerotherapy for vascular anomalies
Alateya, Aysha, Alateya, Zain, Kadirvel, R, Kallmes, D, Brinjikji, Waleed , Ognard, Julien , Hajj, G El , Ghozy, Sherief , Kadirvel, Ramanathan , Kallmes, David F.

Mayo Clinic

SNIS 22nd annual meeting electronic poster abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A242.2-A243

10.1136/jnis-2025-snis.336 Get It